Ann Arfsten

2.9k citations

36 papers · 2.4k indexed · 1 hit paper · h-index 21

Immunology and Allergy top 2%
Cardiology and Cardiovascular Medicine top 2%
- Antiplatelet Therapy and Cardiovascular Diseases 3
- Atrial Fibrillation Management and Outcomes 3
Hematology top 5%
- Blood Coagulation and Thrombosis Mechanisms 8
- Platelet Disorders and Treatments 7
Internal Medicine top 5%
Genetics top 5%
Molecular Biology
- Receptor Mechanisms and Signaling 8
- RNA and protein synthesis mechanisms 6
Surgery
- Heparin-Induced Thrombocytopenia and Thrombosis 4
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 4

Co-authors: Robert M. Scarborough John Lewicki David R. Phillips Judith Miller J G Porter Dale B. Schenk Forrest Fuller Jack W. Rose
Cited by: Immunology and Allergy Cardiology and Cardiovascular Medicine Hematology
Journals: Journal of Biological Chemistry (9 papers)Bioorganic & Medicinal Chemistry Letters (8 papers)Journal of Medicinal Chemistry (3 papers)
Partner nations: United States Germany

In The Last Decade

Ann Arfsten

36 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Ann Arfsten

Since Specialization

Citations

This map shows the geographic impact of Ann Arfsten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Arfsten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Arfsten more than expected).

Fields of papers citing papers by Ann Arfsten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Arfsten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Arfsten. The network helps show where Ann Arfsten may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ann Arfsten, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ann Arfsten Line = papers co-authored together Ann Arfsten links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Hepatitis C Genotype 1a Replicon Improved Through Introduction of Fitness Mutations BioTechniques ·Christian Voitenleitner,Jill Bechtel,Ann Arfsten,Robert Hamatake	2012	4
2	Design, Synthesis and Discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as Highly Potent Factor Xa Inhibitors Chemical and Pharmaceutical Bulletin ·Zhaozhong J. Jia,Robert M. Scarborough,Penglie Zhang,Jag Lally,Ann Arfsten,Uma Sinha,Bing‐Yan Zhu	2009	2
3	Parallel synthesis and structure–activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors Bioorganic & Medicinal Chemistry Letters ·Yaohua Luo,Erick A. Goldman,Wenrong Huang,Ting Su,Lingyan Wang,John Woolfrey,Yanhong Wu,Underwood Malcolm,Ann Arfsten,Brian Huang,Krystyna Moszumańska-Nazar,長千葉,Angelo Pagan,Uma Sinha,Paul Wong,Athiwat Hutchaleelaha,Robert M. Scarborough,Bing‐Yan Zhu	2004	7
4	N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhaozhong J. Jia,Ting Su,Underwood Malcolm,Yanhong Wu,Erick A. Goldman,Wenhao Li,Penglie Zhang,Lane A. Clizbe,Yonghong Song,Yaohua Luo,Wenrong Huang,John Woolfrey,Uma Sinha,Ann Arfsten,Athiwat Hutchaleelaha,Stanley J. Hollenbach,Joseph L. Lambing,Robert M. Scarborough,Bing‐Yan Zhu	2004	12
5	Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity Bioorganic & Medicinal Chemistry Letters ·Penglie Zhang,Liang Bao,Underwood Malcolm,Zhaozhong J. Jia,John Woolfrey,Ann Arfsten,Susan Edwards,Uma Sinha,Athiwat Hutchaleelaha,Joseph L. Lambing,Stanley J. Hollenbach,Robert M. Scarborough,Bing‐Yan Zhu	2004	19
6	1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs Bioorganic & Medicinal Chemistry Letters ·Zhaozhong J. Jia,Yanhong Wu,Wenrong Huang,Penglie Zhang,Lane A. Clizbe,Erick A. Goldman,Uma Sinha,Ann Arfsten,Susan Edwards,P S Basil,Athiwat Hutchaleelaha,Robert M. Scarborough,Bing‐Yan Zhu	2004	19
7	1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhaozhong J. Jia,Yanhong Wu,Wenrong Huang,Penglie Zhang,Yonghong Song,John Woolfrey,Uma Sinha,Ann Arfsten,Susan Edwards,Athiwat Hutchaleelaha,Penny Eisenberg,Joseph L. Lambing,Robert M. Scarborough,Bing‐Yan Zhu	2004	43
8	Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs Bioorganic & Medicinal Chemistry Letters ·Penglie Zhang,Liang Bao,Underwood Malcolm,Erick A. Goldman,Zhaozhong J. Jia,Ann Arfsten,Susan Edwards,Uma Sinha,Athiwat Hutchaleelaha,Gary Park,Joseph L. Lambing,Stanley J. Hollenbach,Robert M. Scarborough,Bing‐Yan Zhu	2004	20
9	Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors Bioorganic & Medicinal Chemistry Letters ·Wenrong Huang,Rina Syafrida Wahyu Laily Putri Rachmawati,Hua Yang,Ting Su,Ch. Gough,Paul Wong,Ann Arfsten,Susan Edwards,Uma Sinha,Stanley J. Hollenbach,Robert M. Scarborough,Bing‐Yan Zhu	2003	13
10	Non-Peptide RGD Surrogates Which Mimic a Gly-Asp β-Turn: Potent Antagonists of Platelet Glycoprotein IIb−IIIa Journal of Medicinal Chemistry ·Matthew J. Fisher,Bruce P. Gunn,Khushal Matai,Allen D. Kline,Jeffrey T. Mullaney,Aboubakr Benbrahim,Robert M. Scarborough,Ann Arfsten,S. H. Jie,Suzane L. Um,Barbara G. Utterback,Joseph A. Jakubowski	1997	37
11	Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists Journal of Medicinal Chemistry ·Daniel J. Sall,Ann Arfsten,신정 굉지,M. Linet,Khushal Matai,Jefferson R. McCowan,J. M. JUN. MORIN,Jack W. Rose,Robert M. Scarborough,Mark S. Smyth,Suzane L. Um,Barbara G. Utterback,Roberto Cervoni,James H. Wikel,Virginia L. Wyss,Joseph A. Jakubowski	1997	15
12	Platelet glycoprotein IIb–IIIa receptor (GPIIb–IIIa) antagonists derived from amidinoindoles Bioorganic & Medicinal Chemistry Letters ·Daniel J. Sall,Ann Arfsten,Chih -Peng Hung,M. Linet,Khushal Matai,Jefferson R. McCowan,Ming-Yaw Huang,Robert M. Scarborough,Suzane L. Um,Barbara G. Utterback,Joseph A. Jakubowski	1996	4
13	Vaccination against the cat flea Ctenocephalides felis felis Parasite Immunology ·Andrew W. Heath,Ann Arfsten,Miles K. Yamanaka,Ki Bum Kim,Beverly A. Dale	1994	23
14	Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA Biochemical and Biophysical Research Communications ·J. Gordon Porter,Ann Arfsten,Forrest Fuller,Judith Miller,Antoine Chami,John Lewicki	1990	94
15	Human and canine gene homologs of porcine brain natriuretic peptide Biochemical and Biophysical Research Communications ·Jeffrey J. Seilhamer,Ann Arfsten,Judith Miller,A. Morgan,Robert M. Scarborough,John Lewicki,J G Porter	1989	106
16	Cloning of a cDNA Encoding Porcine Brain Natriuretic Peptide Journal of Biological Chemistry ·J G Porter,Ann Arfsten,S. Jack Willey,Robert M. Scarborough,John Lewicki,Jeffrey J. Seilhamer	1989	42
17	Human renin is correctly processed and targeted to the regulated secretory pathway in mouse pituitary AtT-20 cells. Journal of Biological Chemistry ·L C Fritz,Abebe Mola Bogale,Ann Arfsten,James W. Schilling,Cynthia T. Carilli,John Shine,John D. Baxter,Tim L. Reudelhuber	1987	45
18	Molecular cloning and characterization of mouse mammary tumor proviruses from a T-cell lymphoma Journal of Virology ·Jaquelin P. Dudley,Ann Arfsten,Chih-Li Lilian Hsu,Christine A. Kozak,R Risser	1986	38
19	Phenotypic variation in clonal Abelson virus lymphoma cells. The Journal of Immunology ·Mert ARTUK,William W. Lamph,Jaquelin P. Dudley,Ann Arfsten,R Risser,Lewis L. Lanier,N.L. Warner,J S Tung,Margrit P. Scheid	1985	15
20	Isolation and characterization of a promoter mutant in the str ribosomal protein operon in E. coli Cell ·Leonard Post,Ann Arfsten,Michio Nomura,S. Richard Jaskunas	1978	21

About Ann Arfsten

Ann Arfsten is a scholar working on Hematology, Immunology and Allergy and Cardiology and Cardiovascular Medicine, having authored 36 papers that have together received 2.4k indexed citations. Recurring topics across this work include Blood Coagulation and Thrombosis Mechanisms (8 papers), Receptor Mechanisms and Signaling (8 papers), Platelet Disorders and Treatments (7 papers), RNA and protein synthesis mechanisms (6 papers), Heparin-Induced Thrombocytopenia and Thrombosis (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Atrial Fibrillation Management and Outcomes (3 papers). The work is most often cited by research in Immunology and Allergy (303 citations), Cardiology and Cardiovascular Medicine (934 citations) and Hematology (329 citations). Ann Arfsten has collaborated with scholars based in United States and Germany. Frequent co-authors include Robert M. Scarborough, John Lewicki, David R. Phillips, Judith Miller, J G Porter, Dale B. Schenk, Forrest Fuller, Jack W. Rose, Israel Charo and Andrew Campbell. Their work appears in journals such as Journal of Biological Chemistry, Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Proceedings of the National Academy of Sciences and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact